{"id":45886,"date":"2022-07-06T22:01:49","date_gmt":"2022-07-06T20:01:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/"},"modified":"2022-07-06T22:01:49","modified_gmt":"2022-07-06T20:01:49","slug":"atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/","title":{"rendered":"Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022"},"content":{"rendered":"
\n

\nLive Conference Call and Webcast at 5:00 p.m. EDT<\/i>\n<\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc.<\/a> (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will disclose its completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis via press release after market close on Tuesday, July 12, 2022. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. EDT.\n<\/p>\n

<\/a><\/p>\n

\nAnalysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID 13731189. A live audio webcast can be accessed by visiting the Investors & Media \u2013 News & Events<\/a> section of atarabio.com<\/a>. An archived replay will be available on the Company’s website for 30 days following the live webcast.\n<\/p>\n

\nAbout Atara Biotherapeutics, Inc.<\/b>\n<\/p>\n

\nAtara Biotherapeutics, Inc.<\/a> (@Atarabio<\/a>) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel\u00ae<\/sup> (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients\u2019 lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com<\/a> and follow us on Twitter<\/a> and LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nINVESTORS & MEDIA:<\/b>
Investors<\/i><\/b>
Eric Hyllengren
\n
805-395-9669
\n
ehyllengren@atarabio.com<\/a>\n<\/p>\n

\nMedia<\/i><\/b>
Alex Chapman
\n
805-456-4772
\n
achapman@atarabio.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Live Conference Call and Webcast at 5:00 p.m. EDT SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will disclose its completion of the ATA188 Phase … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45886","6":"format-standard","7":"category-industry"},"yoast_head":"\nAtara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Live Conference Call and Webcast at 5:00 p.m. EDT SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will disclose its completion of the ATA188 Phase ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-06T20:01:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220706005779\/en\/778671\/21\/Atara-Bio1_logo_300x185-1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022\",\"datePublished\":\"2022-07-06T20:01:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/\"},\"wordCount\":424,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005779\\\/en\\\/778671\\\/21\\\/Atara-Bio1_logo_300x185-1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/\",\"name\":\"Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005779\\\/en\\\/778671\\\/21\\\/Atara-Bio1_logo_300x185-1.jpg\",\"datePublished\":\"2022-07-06T20:01:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005779\\\/en\\\/778671\\\/21\\\/Atara-Bio1_logo_300x185-1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220706005779\\\/en\\\/778671\\\/21\\\/Atara-Bio1_logo_300x185-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/","og_locale":"en_US","og_type":"article","og_title":"Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022 - Pharma Trend","og_description":"Live Conference Call and Webcast at 5:00 p.m. EDT SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will disclose its completion of the ATA188 Phase ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-06T20:01:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220706005779\/en\/778671\/21\/Atara-Bio1_logo_300x185-1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022","datePublished":"2022-07-06T20:01:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/"},"wordCount":424,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220706005779\/en\/778671\/21\/Atara-Bio1_logo_300x185-1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/","url":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/","name":"Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220706005779\/en\/778671\/21\/Atara-Bio1_logo_300x185-1.jpg","datePublished":"2022-07-06T20:01:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220706005779\/en\/778671\/21\/Atara-Bio1_logo_300x185-1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220706005779\/en\/778671\/21\/Atara-Bio1_logo_300x185-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-announce-completion-of-ata188-phase-2-embold-study-interim-analysis-on-tuesday-july-12-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45886"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45886\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}